Global Choroidal Neovascularization Market Size By Type (Intravenous, Intravitreal), By Application (Extreme Myopia, Malignant Myopic Degeneration), By Region, And Segment Forecasts, 2023 to 2032

The Global Choroidal Neovascularization (CNV) Market was valued at USD X billion in 2023 and is projected to surpass USD X billion by 2031, growing at a CAGR of X% during the forecast period of 2023 to 2031. The rising prevalence of age-related macular degeneration (AMD) and other retinal disorders is significantly driving market growth. Choroidal neovascularization (CNV) is a severe condition caused by abnormal blood vessel growth in the choroid, leading to vision impairment and blindness. With increasing awareness, technological advancements, and the introduction of novel therapeutics, the market is poised for significant expansion.

Drivers

1. Increasing Prevalence of Age-Related Macular Degeneration (AMD)

AMD is one of the leading causes of blindness among the aging population worldwide. As the global elderly population increases, so does the incidence of CNV-related conditions, thereby fueling demand for advanced treatment solutions.

2. Advancements in Pharmacological Therapies

Breakthroughs in anti-VEGF (vascular endothelial growth factor) therapies have revolutionized CNV treatment. Drugs like Ranibizumab, Bevacizumab, and Aflibercept have improved patient outcomes, making CNV treatments more effective and accessible.

3. Growing Investment in Ophthalmic Research

Government initiatives, private investments, and increasing clinical trials in ophthalmology are supporting the development of novel therapies for CNV. The rise in funding for vision-related disorders is accelerating product innovation.

Restraints

1. High Cost of Treatment

Anti-VEGF injections and other treatment modalities for CNV are expensive, making them inaccessible for patients in developing and underdeveloped regions. This poses a challenge to widespread market penetration.

2. Lack of Awareness and Diagnosis in Emerging Economies

In many regions, a lack of awareness about retinal diseases leads to late-stage diagnoses, reducing treatment efficacy and patient outcomes. Limited access to advanced diagnostic tools in low-income areas further hinders market growth.

Opportunity

1. Expansion into Emerging Markets

Asia-Pacific, Latin America, and the Middle East & Africa are witnessing a surge in healthcare infrastructure development. Government initiatives to improve ophthalmic care create substantial opportunities for market players to expand their footprint.

2. Development of Gene and Stem Cell Therapies

Innovative treatments such as gene therapy and stem cell therapy hold immense potential for CNV treatment, addressing underlying causes rather than just symptoms. Companies investing in these novel approaches can gain a competitive advantage.

Market by Treatment Type Insights

1. Anti-VEGF Therapy (Largest Segment)

Anti-VEGF therapy is the gold standard for CNV treatment, accounting for the largest revenue share in 2023. Drugs like Ranibizumab (Lucentis), Bevacizumab (Avastin), and Aflibercept (Eylea) dominate the market due to their high efficacy in slowing disease progression.

2. Photodynamic Therapy (PDT)

While declining in usage due to the emergence of anti-VEGF drugs, PDT remains an alternative for patients unresponsive to standard treatment. Verteporfin-based PDT continues to be used in specific cases.

3. Laser Photocoagulation

Historically used for CNV treatment, laser photocoagulation has seen a decline with the advent of targeted drug therapies. However, it remains relevant in certain subtypes of CNV.

Market by End-Use Insights

1. Hospitals (Largest Segment)

Hospitals account for the highest revenue share in the CNV market, driven by advanced diagnostic capabilities, specialized ophthalmology departments, and high patient inflow.

2. Specialty Clinics

Specialized retinal clinics are gaining traction due to their focus on treating macular disorders, providing targeted care for CNV patients.

3. Ambulatory Surgical Centers (ASCs)

With rising outpatient procedures and minimally invasive treatment options, ASCs are emerging as a cost-effective alternative for CNV treatments.

Market by Regional Insights

1. North America (Largest Market)

North America dominates the global CNV market due to high healthcare expenditure, advanced ophthalmic research, and the presence of leading pharmaceutical companies. The U.S. and Canada are key contributors.

2. Europe

Europe holds a significant market share with strong healthcare infrastructure, favorable reimbursement policies, and increasing adoption of new therapies. The UK, Germany, and France lead the region.

3. Asia-Pacific (Fastest Growing Market)

Asia-Pacific is projected to witness the highest growth rate, driven by rising geriatric population, increasing healthcare awareness, and improving accessibility to ophthalmic treatments. China, India, and Japan are key growth centers.

4. Latin America & Middle East & Africa

While currently holding a smaller market share, these regions present lucrative opportunities for expansion, particularly with increasing government initiatives and investments in healthcare infrastructure.

Competitive Scenario

Key players in the Global Choroidal Neovascularization Market include:

Roche Holdings AG (Genentech)

Novartis AG

Bayer AG

Regeneron Pharmaceuticals, Inc.

Allergan (AbbVie)

Bausch + Lomb

Santen Pharmaceutical

Alcon, Inc.

Apellis Pharmaceuticals

Graybug Vision

These companies are actively engaged in drug development, strategic partnerships, acquisitions, and clinical trials to strengthen their market position.

Key Market Developments

2023: Roche launched an extended-duration anti-VEGF therapy, reducing the number of required injections for CNV patients.

2024: Regeneron announced positive Phase III results for its next-generation CNV therapy, showing superior efficacy over existing treatments.

2025: Novartis entered into a strategic collaboration with a biotech firm for gene therapy research targeting CNV.

Scope of Work – Global Choroidal Neovascularization Market